Who should attend?
Those involved in the development and manufacture of generic orally inhaled and nasal drug products (OINDPs). Anyone interested in complex drug deformulation and development, and in the possibilities of and requirements for establishing bioequivalence in vitro.
What will you learn?
How physicochemical measurement techniques can be applied to speed the deformulation of complex drug products such as orally inhaled and nasal drug products. Also, how these technologies are used to help establish Q3 bioequivalence for nasal sprays, and how they may be applied to other OINDPs such as dry powder inhalers (DPIs) in the future.